bosutinib — United Healthcare

Initial criteria

• Diagnosis of Philadelphia chromosome-positive acute lymphoblastic leukemia

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Bosulif therapy

Approval duration

12 months